Eli Lilly's $7 billion deal for Kelonia Therapeutics on Monday was just the latest example | Despite the recent “feeding ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Thermo Fisher Scientific reported “a strong start to the year,” buoyed by strong demand from its pharma and biotech customers ...

The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...

Avalyn Pharma is hoping to rake in around $182 million from an IPO, which the biotech will use to take its inhaled versions ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...